_id
69148e67ccc777a4e85d9b2f
Ticker
PLTT
Name
Pilot Therapeutics Holdings Inc
Exchange
OTCCE
Address
101 N. Chestnut Street, Winston-Salem, NC, United States, 27101
Country
USA
Sector
Industrials
Industry
Specialty Business Services
Currency
USD
Website
-
Description
Pilot Therapeutics Holdings Inc. develops and manufactures pharmaceutical products for treatment of dysfunctional lipid metabolism. The company offers Airozin for asthma, PLT 1288 for arthritis, PLT 732 for cardiovascular disease and diabetes, and PLT 2753 for allergic rhinitis. Additionally, it provides clinical trials, personnel recruitment, sales and marketing, and raising capital services. Pilot Therapeutics Holdings Inc. was founded in 1998 and is based in Winston-Salem, North Carolina.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2025-11-12T13:40:55.002Z
Image
-
Ipo Date
-
Market Cap
923783
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2003-06-30
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
1671439
Operating Income
-1671439
Interest Expense
191541
Pretax Income
-1862418
Net Income
-1862418
Eps
-
Dividends Per Share
-
Shares Outstanding
-
Income Tax Expense
0
EBITDA
-
Total Other Income Expense Net
-
Cash
97109
Short Term Investments
-
Receivables
515741
Inventories
341005
Total Current Assets
1118620
Property Plant Equipment
223746
Total Assets
3987230
Payables
1423778
Short Term Debt
5411227
Long Term Debt
5011227
Total Liabilities
13579968
Equity
-9592738
Depreciation
7368
Change In Working Capital
-
Cash From Operations
-1078762
Capital Expenditures
76812
Cash From Investing
-76812
Cash From Financing
890808
Net Change In Cash
-264766
PE
-
PB
-
ROE
19.414874043260642
ROA
-46.70957030319294
FCF
-1155574
Fcf Percent
-
Piotroski FScore
1
Health Score
48
Deep Value Investing Score
1
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
1.5
Growth Investing Score
1
Momentum Investing Score
2
Net Net Investing Score
0.5
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2003-06-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
1671439
Quarters > 0 > income Statement > operating Income
-1671439
Quarters > 0 > income Statement > interest Expense
191541
Quarters > 0 > income Statement > pretax Income
-1862418
Quarters > 0 > income Statement > net Income
-1862418
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
97109
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
515741
Quarters > 0 > balance Sheet > inventories
341005
Quarters > 0 > balance Sheet > total Current Assets
1118620
Quarters > 0 > balance Sheet > property Plant Equipment
223746
Quarters > 0 > balance Sheet > total Assets
3987230
Quarters > 0 > balance Sheet > payables
1423778
Quarters > 0 > balance Sheet > short Term Debt
5411227
Quarters > 0 > balance Sheet > long Term Debt
5011227
Quarters > 0 > balance Sheet > total Liabilities
13579968
Quarters > 0 > balance Sheet > equity
-9592738
Quarters > 0 > cash Flow > net Income
-1862418
Quarters > 0 > cash Flow > depreciation
7368
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-1078762
Quarters > 0 > cash Flow > capital Expenditures
76812
Quarters > 0 > cash Flow > cash From Investing
-76812
Quarters > 0 > cash Flow > cash From Financing
890808
Quarters > 0 > cash Flow > net Change In Cash
-264766
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
19.414874043260642
Quarters > 0 > ratios > ROA
-46.70957030319294
Quarters > 0 > ratios > FCF
-1155574
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
48
Quarters > 1 > quarter
2003-03-31
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
0
Quarters > 1 > income Statement > gross Profit
0
Quarters > 1 > income Statement > operating Expenses
1551826
Quarters > 1 > income Statement > operating Income
-1551826
Quarters > 1 > income Statement > interest Expense
251047
Quarters > 1 > income Statement > pretax Income
-1798703
Quarters > 1 > income Statement > net Income
-1798703
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
361875
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
500000
Quarters > 1 > balance Sheet > inventories
370767
Quarters > 1 > balance Sheet > total Current Assets
1554532
Quarters > 1 > balance Sheet > property Plant Equipment
154303
Quarters > 1 > balance Sheet > total Assets
4353699
Quarters > 1 > balance Sheet > payables
1087731
Quarters > 1 > balance Sheet > short Term Debt
4889034
Quarters > 1 > balance Sheet > long Term Debt
4889034
Quarters > 1 > balance Sheet > total Liabilities
12168168
Quarters > 1 > balance Sheet > equity
-7814469
Quarters > 1 > cash Flow > net Income
-1798703
Quarters > 1 > cash Flow > depreciation
7068
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-1712224
Quarters > 1 > cash Flow > capital Expenditures
52923
Quarters > 1 > cash Flow > cash From Investing
-52923
Quarters > 1 > cash Flow > cash From Financing
-81139
Quarters > 1 > cash Flow > net Change In Cash
-1846286
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
23.017597228935198
Quarters > 1 > ratios > ROA
-41.314362798163124
Quarters > 1 > ratios > FCF
-1765147
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
49
Quarters > 2 > quarter
2002-12-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
1090755
Quarters > 2 > income Statement > operating Income
-1090755
Quarters > 2 > income Statement > interest Expense
274027
Quarters > 2 > income Statement > pretax Income
-1390175
Quarters > 2 > income Statement > net Income
-1390175
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
2208161
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
353605
Quarters > 2 > balance Sheet > total Current Assets
2907686
Quarters > 2 > balance Sheet > property Plant Equipment
108448
Quarters > 2 > balance Sheet > total Assets
5712902
Quarters > 2 > balance Sheet > payables
1382575
Quarters > 2 > balance Sheet > short Term Debt
4797980
Quarters > 2 > balance Sheet > long Term Debt
4766841
Quarters > 2 > balance Sheet > total Liabilities
11747942
Quarters > 2 > balance Sheet > equity
-6035040
Quarters > 2 > cash Flow > net Income
-1390175
Quarters > 2 > cash Flow > depreciation
13542
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-2463978
Quarters > 2 > cash Flow > capital Expenditures
5625
Quarters > 2 > cash Flow > cash From Investing
-5625
Quarters > 2 > cash Flow > cash From Financing
4546615
Quarters > 2 > cash Flow > net Change In Cash
2077013
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
23.035058591160954
Quarters > 2 > ratios > ROA
-24.333954967195307
Quarters > 2 > ratios > FCF
-2469603
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
48
Quarters > 3 > quarter
2002-09-30
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
995296
Quarters > 3 > income Statement > operating Income
-995296
Quarters > 3 > income Statement > interest Expense
224126
Quarters > 3 > income Statement > pretax Income
-1217622
Quarters > 3 > income Statement > net Income
-1217622
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
131148
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
166588
Quarters > 3 > balance Sheet > total Current Assets
909867
Quarters > 3 > balance Sheet > property Plant Equipment
111833
Quarters > 3 > balance Sheet > total Assets
3718468
Quarters > 3 > balance Sheet > payables
1650608
Quarters > 3 > balance Sheet > short Term Debt
3257735
Quarters > 3 > balance Sheet > long Term Debt
3144648
Quarters > 3 > balance Sheet > total Liabilities
8473769
Quarters > 3 > balance Sheet > equity
-4755301
Quarters > 3 > cash Flow > net Income
-1217622
Quarters > 3 > cash Flow > depreciation
13542
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-767960
Quarters > 3 > cash Flow > capital Expenditures
5625
Quarters > 3 > cash Flow > cash From Investing
-5625
Quarters > 3 > cash Flow > cash From Financing
780810
Quarters > 3 > cash Flow > net Change In Cash
12849
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
25.605571550570616
Quarters > 3 > ratios > ROA
-32.745259606913386
Quarters > 3 > ratios > FCF
-773585
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
49
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
19.414874043260642
Profitability > metrics > ROA
-166.49246392876938
Profitability > final Score
54
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-8.726272704016372
Risk > final Score
-5
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.16366045087018957
Liquidity > metrics > Quick Ratio
0.1137694851722859
Liquidity > final Score
16
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
55
Prev Profitabilities > 2
55
Prev Risks > 0
5
Prev Risks > 1
14
Prev Risks > 2
12
Prev Liquidities > 0
20
Prev Liquidities > 1
31
Prev Liquidities > 2
18
Updated At
2026-01-20T22:24:13.337Z
Pilot Therapeutics Holdings Inc. develops and manufactures pharmaceutical products for treatment of dysfunctional lipid metabolism. The company offers Airozin for asthma, PLT 1288 for arthritis, PLT 732 for cardiovascular disease and diabetes, and PLT 2753 for allergic rhinitis. Additionally, it provides clinical trials, personnel recruitment, sales and marketing, and raising capital services. Pilot Therapeutics Holdings Inc. was founded in 1998 and is based in Winston-Salem, North Carolina.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AA Bid for Leggett & Platt: Restructuring and Acquisition Prospects Collide AD HOC NEWS
Read more →Truist Securities reiterates Hold rating on Leggett and Platt stock Investing.com
Read more →Showing 2 of 10
(Last Updated 2003-06-30)
Health Score
Return on Equity (ROE)
-
High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Pilot Therapeutics Holdings Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2003-06-30)
(Last Updated 2003-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
(Last Updated 2003-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2003-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.